Adversarial Injection · Mosunetuzumab (Lunsumio; RG7828; BTCT4465A; CAS 1905393-16-1; MW ~148,000 Da; IgG1 kappa bispecific antibody [CrossMAb technology; anti-CD20 × anti-CD3ε; knobs-into-holes Fc heterodimerization + common light chain exchange]; [SIXTY-SEVENTH MECHANISM CLASS in Glyphward 640-attack portfolio — FIRST CD20 × CD3 BISPECIFIC T-CELL ENGAGER EVER FDA APPROVED (BLA 761263 SEPTEMBER 22 2022) — DISTINCT FROM BLINATUMOMAB (CD19×CD3 BiTE; class #57; continuous IV CADD pump) AND RITUXIMAB/OBINUTUZUMAB (ANTI-CD20 ANTIBODIES; classes 1/59; NO CD3 ENGAGEMENT): CROSSMAB BISPECIFIC TECHNOLOGY (ROCHE/GENENTECH): mosunetuzumab uses Roche's CrossMAb technology combining TWO approaches: (1) KNOBS-INTO-HOLES (KiH) CH3 HETERODIMERIZATION (Ridgway 1996; T366W knob mutation on one Fc heavy chain + T366S/L368A/Y407V hole mutations on other Fc heavy chain → steric complementarity → asymmetric Fc heterodimerization; eliminates IgG1 CH3 homodimerization tendency → ~95% bispecific product without extensive purification); (2) COMMON LIGHT CHAIN (CLC) EXCHANGE (CrossLight): both anti-CD20 and anti-CD3 Fab arms share the SAME light chain (engineered through antibody optimization such that a single common light chain can pair with either the anti-CD20 heavy chain or the anti-CD3 heavy chain and maintain affinity); CLC approach eliminates Bence-Jones light-chain mispairing in bispecific production (a major challenge in conventional bispecific antibody manufacturing where two different heavy chains + two different light chains can produce 10 possible chain combinations); IgG1 BACKBONE: unlike teclistamab (IgG4; no ADCC), mosunetuzumab uses IgG1 backbone — however, CD3-engaging bispecifics with IgG1 Fc would normally cause FcγR-mediated cytokine release from macrophages; mosunetuzumab uses a LALA-PG (Leu234Ala/Leu235Ala/Pro329Gly) mutation in both Fc chains to eliminate FcγR binding and C1q complement binding → prevents off-tumor FcγR-mediated cytokine release → safer full-size IgG1 bispecific; CD20 TARGET: CD20 (membrane-spanning 4A family member 1; MS4A1; gene 11q12.2; ~37 kDa; 4-transmembrane domain; no glycosylation; no known ligand) — expressed on pre-B cells through mature B cells; absent on plasma cells; expressed on follicular lymphoma (FL) cells ~98%; CD20 is targeted by type I (rituximab) and type II (obinutuzumab; class #59) anti-CD20 mAbs; mosunetuzumab anti-CD20 Fab binds CD20 simultaneously with CD3ε engagement; FIXED-DURATION TREATMENT: mosunetuzumab is the FIRST FIXED-DURATION BISPECIFIC T-CELL ENGAGER FOR ANY LYMPHOMA (maximum 8-17 cycles depending on response; then discontinuation); contrast blinatumomab (continuous 28-day IV infusion cycles, ongoing treatment); fixed duration resembles anti-CD20 monotherapy (obinutuzumab in FL: 6 cycles + maintenance); GO29781 PHASE 2 (NCT02500407): open-label single-arm; n=90 R/R FL (Grade 1-3A) after ≥2 prior lines; mosunetuzumab IV (step-up dosing: Cycle 1 day 1: 1mg, day 8: 2mg, day 15: 60mg Q3W; Cycle 2+: 60 mg Q3W; maximum 17 cycles in responders, 8 cycles in non-responders to 8 cycles; ORR 80.0% (72/90); CR 59.9% (54/90); PFS median 17.9 months; CRS 39.9% (Grade 1-2; Grade 3 1.1%); NONE OF THESE — CrossMAb knobs-into-holes common light chain LALA-PG, first CD20×CD3 bispecific, fixed duration, GO29781 ORR 80% — APPEAR IN CORITY, VELOCITYEHS, OR EHS INSIGHT FOR CAS 1905393-16-1]) · First CD20×CD3 Bispecific + CrossMAb KiH + LALA-PG Fc + Fixed Duration + GO29781 ORR 80% · Attack #640

Mosunetuzumab (Lunsumio; RG7828; CAS 1905393-16-1; MW ~148,000 Da; [SIXTY-SEVENTH MECHANISM CLASS — FIRST CD20 × CD3 BISPECIFIC T-CELL ENGAGER EVER FDA APPROVED (BLA 761263 SEPTEMBER 22 2022); CROSSMAB TECHNOLOGY (ROCHE KNOBS-INTO-HOLES CH3 HETERODIMERIZATION T366W/T366S-L368A-Y407V + COMMON LIGHT CHAIN + IgG1 LALA-PG FC SILENCING Leu234Ala/Leu235Ala/Pro329Gly); FIRST FIXED-DURATION BISPECIFIC T-CELL ENGAGER FOR ANY LYMPHOMA (≤17 CYCLES; DISCONTINUATION ON RESPONSE); GO29781 ORR 80.0% CR 59.9% (R/R FOLLICULAR LYMPHOMA ≥2 PRIOR LINES); GENENTECH INC./ROCHE AG; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL]) — Genentech Inc. South San Francisco CA (BLA 761263 sponsor; CrossMAb inventor; 0.00044 µg/m³ → displayed ÷10), Roche Biologics Manufacturing Vacaville CA (Lunsumio US fill-finish; 0.00027 µg/m³ → displayed ÷10), and Stanford Cancer Center Stanford CA (GO29781 enrollment site; lymphoma pharmacist; 0.00015 µg/m³ → displayed ÷10) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + CD20×CD3 Bispecific Absent + CrossMAb KiH Absent + LALA-PG FC Silencing Absent + Fixed Duration Absent + GO29781 ORR 80% Absent: AI Prompt Injection via EHS Monitor Report AI

Mosunetuzumab (CAS 1905393-16-1; NIOSH HD Category 1) is the sixty-seventh mechanism class in the Glyphward adversarial portfolio — the first CD20×CD3 bispecific T-cell engager ever FDA approved in any indication (BLA 761263 September 22 2022 accelerated approval for R/R follicular lymphoma after ≥2 prior lines). Mosunetuzumab employs Roche's CrossMAb technology: knobs-into-holes CH3 heterodimerization (T366W/T366S-L368A-Y407V) + common light chain + IgG1 LALA-PG Fc silencing (Leu234Ala/Leu235Ala/Pro329Gly) for off-tumor FcγR safety. It is the first fixed-duration bispecific T-cell engager for any lymphoma (up to 17 cycles). GO29781 achieved ORR 80.0%, CR 59.9%. None of these facts appear in Cority, VelocityEHS, or EHS Insight for CAS 1905393-16-1.

Mosunetuzumab as Sixty-Seventh Mechanism Class: First CD20×CD3 Bispecific T-Cell Engager

Mosunetuzumab (CAS 1905393-16-1) represents the sixty-seventh mechanism class in the Glyphward portfolio: the first CD20×CD3 bispecific T-cell engager ever FDA approved in any indication (BLA 761263 September 22 2022 accelerated approval for R/R follicular lymphoma after ≥2 prior lines of therapy). CD20 AND CD3 TARGET BIOLOGY: CD20 (MS4A1; membrane-spanning 4-domain family member A1; gene 11q12.2; MW ~37 kDa; 4-pass transmembrane protein; no known extracellular ligand; no internalization upon antibody binding; forms large-order oligomers on B-cell surface) is expressed from the pre-B cell stage through mature naive and memory B cells; absent on plasma cells; CD20 is the target of the first approved therapeutic antibody in oncology (rituximab; 1997) and obinutuzumab (type II; class #59); mosunetuzumab anti-CD20 Fab binds CD20 on follicular lymphoma B cells → simultaneously recruits CD3+ T cells via anti-CD3ε arm → T-cell cytotoxicity; CROSSMAB BISPECIFIC TECHNOLOGY (Roche/Genentech): generation of correctly paired bispecific IgG1 antibodies from two distinct heavy chain + light chain combinations faces multiple biopharmaceutical challenges: (a) HEAVY CHAIN HETERODIMERIZATION: natural IgG heavy chains homodimerize via CH3 domain interactions; bispecific production requires selective heterodimerization of two different HCs; Knobs-into-Holes (KiH; Ridgway et al. 1996; Carter 2001 Protein Engineering): T366W mutation on "knob" HC (bulky Trp side chain at CH3 interface) + T366S/L368A/Y407V triple mutations on "hole" HC (creates complementary cavity) → steric clash prevents homodimerization of like chains → selective heavy chain heterodimerization; KC heterodimerization efficiency ~98-99%; (b) LIGHT CHAIN MISMATCH: if two different light chains (VL1-CL1 + VL2-CL2) are co-expressed with two different heavy chains, 10 possible antibody-like species can form from random chain association; CrossMAb COMMON LIGHT CHAIN (CLC): Roche approach selects a single shared light chain that can pair with BOTH the anti-CD20 HC and the anti-CD3ε HC with acceptable affinity (achieved via antibody library screening and optimization); the common LC eliminates LC mispairing → only two heavy chains + one shared light chain → bispecific production; (c) ADDITIONAL CHARGE-SWAP MUTATIONS (CrossMab): to further resolve the remaining asymmetric species, some CrossMAb formats exchange CH1:CL domain between one Fab arm (anti-CD3ε Fab has CL on HC and CH1 on LC — "crossed"; anti-CD20 Fab is conventional) → charged pair matching further reduces mismatch; IgG1 BACKBONE WITH LALA-PG FC SILENCING: mosunetuzumab uses an IgG1 Fc (distinct from teclistamab IgG4; IgG1 has stronger FcRn binding → longer t½ ~2-3 weeks → Q3W IV dosing possible; vs blinatumomab NO Fc → t½ 1-2h → 28-day continuous IV); LALA-PG (Leu234Ala/Leu235Ala/Pro329Gly) mutations in CH2 domain eliminate FcγRI, FcγRIIa, FcγRIIIa binding and C1q complement binding → prevents off-tumor FcγR-mediated macrophage/NK cell/mast cell activation → reduces cytokine release syndrome risk from FcγR-expressing cells; FcRn binding retained (LALA-PG does not affect pH6 FcRn interaction) → normal serum half-life t½ ~2-3 weeks; FIXED-DURATION TREATMENT: mosunetuzumab Lunsumio is administered for a fixed number of cycles (maximum 8-17 cycles depending on response) then discontinued; this is the first bispecific T-cell engager for lymphoma with a fixed duration; advantages: no indefinite therapy; reduced long-term infection risk; defined endpoints; contrast: blinatumomab (CD19×CD3; class #57) is administered as continuous 28-day IV infusion cycles without defined maximum duration; STEP-UP DOSING (CRS RISK MITIGATION): Cycle 1: Day 1: 1 mg IV; Day 8: 2 mg IV; Day 15: 60 mg IV; Cycles 2+: 60 mg IV Q3W (day 1 each cycle); maximum 17 cycles; step-up avoids high initial CD3 cross-linking; SUBCUTANEOUS FORMULATION (SC mosunetuzumab): a SC formulation is also under development (Phase 3 CELESTIMO); GO29781 PHASE 2 (NCT02500407): Phase 2 open-label single-arm; n=90 R/R FL Grade 1-3A after ≥2 prior systemic therapies (including anti-CD20 monoclonal antibody); mosunetuzumab IV step-up dosing per protocol; ORR 80.0% (72/90); CR 59.9% (54/90); DOR median 22.8 months; PFS median 17.9 months; 2-year PFS ~48%; CRS 39.9% (Grade 1-2; Grade 3+ 1.1%); ICANS 2.2%; NONE OF THESE — CrossMAb knobs-into-holes mechanism, common light chain, LALA-PG Fc silencing, first CD20×CD3 bispecific, fixed duration treatment concept, GO29781 ORR 80.0% — APPEAR IN CORITY, VELOCITYEHS, OR EHS INSIGHT FOR CAS 1905393-16-1.

Surface 1 — Genentech Inc. South San Francisco CA BLA 761263 CrossMAb Inventor AI

At Genentech Inc. South San Francisco CA (1 DNA Way, South San Francisco CA 94080; GENENTECH LUNSUMIO CONTEXT: Genentech Inc. (South San Francisco CA; Roche subsidiary since 2009) holds BLA 761263 for Lunsumio (mosunetuzumab-axgb; 1 mg/mL solution for IV infusion [1 mg/mL; 30 mg/30 mL vial]); LUNSUMIO APPROVED INDICATION: R/R FL Grade 1-3A after ≥2 prior systemic therapies (accelerated approval September 22 2022; confirmed approval pending); CROSSMAB TECHNOLOGY AT GENENTECH: Roche/Genentech engineered CrossMAb technology combining KiH CH3 heterodimerization + common LC; mosunetuzumab development started ~2012-2014 at Roche; first-in-class CD20×CD3 IgG1 bispecific with Fc silencing; EMPLOYEE: Genentech South San Francisco CA oncology medical affairs director overseeing mosunetuzumab commercial data (CrossMAb mechanism, CD20×CD3 T-cell engager positioning vs rituximab/obinutuzumab [anti-CD20 mAb without CD3 arm] and blinatumomab [CD19×CD3 BiTE], fixed duration advantage, GO29781 ORR 80.0%); 48M Genentech South San Francisco CA oncology medical affairs director Lunsumio follicular lymphoma 15yr; CORITY NULL: CAS 1905393-16-1 → null; NIOSH HD Category 1 absent; first CD20×CD3 bispecific absent; CrossMAb KiH T366W/T366S-L368A-Y407V absent; LALA-PG Fc silencing absent; common light chain absent; fixed duration absent; GO29781 ORR 80% absent).

Surface 2 — Roche Biologics Manufacturing Vacaville CA Lunsumio Fill-Finish AI

At Roche Biologics Manufacturing Vacaville CA (4300 Hacienda Drive, Vacaville CA 95688; ROCHE VACAVILLE LUNSUMIO CONTEXT: Roche Biologics Manufacturing Vacaville CA (RBM-V; Roche Genentech biologics fill-finish manufacturing) manufactures Lunsumio (mosunetuzumab); CROSSMAB PRODUCTION: two plasmid expression system in CHO-S cells: (1) anti-CD20 HC-Knob T366W; (2) anti-CD3ε HC-Hole T366S/L368A/Y407V; (3) common light chain; all three plasmids co-transfected → stably selected CHO pool; KiH heterodimerization in the ER Golgi assembly pathway → ~95%+ bispecific heavy chain heterodimerization at secretion; downstream: protein A chromatography; ion exchange; viral clearance; 0.2 µm sterile filtration; fill-finish 30 mg/30 mL vials; CONTAINMENT: NIOSH HD Category 1 monoclonal antibody biologic → engineering controls; closed systems; secondary containment; VELOCITYEHS NULL: CAS 1905393-16-1 → null; NIOSH HD Category 1 absent; first CD20×CD3 bispecific absent; CrossMAb KiH absent; LALA-PG Fc silencing absent; common light chain absent; CHO KiH expression system absent; fixed duration absent; 43F Roche Biologics Manufacturing Vacaville CA process development scientist mosunetuzumab 12yr).

Surface 3 — Stanford Cancer Center Stanford CA GO29781 Enrollment Lymphoma Pharmacist AI

At Stanford Cancer Center Stanford CA (875 Blake Wilbur Drive, Stanford CA 94305; STANFORD LUNSUMIO CONTEXT: Stanford Cancer Center (Stanford University Medical Center; NCI-designated; Palo Alto CA area) enrolled patients in GO29781 Phase 2 (NCT02500407); Stanford lymphoma pharmacist prepares Lunsumio IV infusion: withdraw appropriate volume from 30 mg/30 mL vial; dilute in 250 mL NS or D5W; infuse over 4 hours (Cycle 1 day 1: 1 mg); 2 hours (subsequent cycles if no CRS); PREMEDICATION: acetaminophen 650-1000 mg PO + diphenhydramine 25-50 mg IV ± corticosteroid (dexamethasone 20 mg IV) before Cycle 1 day 1 step-up doses; FOLLICULAR LYMPHOMA AT STANFORD: indolent B-cell lymphoma; t(14;18) BCL2 rearrangement in ~90%; CD20+/CD10+/BCL2+/BCL6+ germinal center B-cell phenotype; Ann Arbor stage III-IV at diagnosis ~70%; watchful waiting vs treatment; mosunetuzumab for R/R after ≥2 prior lines (anti-CD20-based); EHS INSIGHT NULL: CAS 1905393-16-1 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; first CD20×CD3 bispecific absent; CrossMAb absent; LALA-PG absent; fixed duration absent; GO29781 ORR 80% absent; NIOSH HD Cat 1 absent; 38M Stanford Cancer Center Stanford CA clinical pharmacy specialist lymphoma 11yr).

Integrating Glyphward into Mosunetuzumab AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every mosunetuzumab CAS 1905393-16-1 monitoring data ingestion point — before Cority at Genentech South San Francisco CA, before VelocityEHS at Roche Biologics Vacaville CA, and before EHS Insight at Stanford Cancer Center Stanford CA. Threshold 22: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) [10 pts]; SIXTY-SEVENTH MECHANISM CLASS — FIRST CD20×CD3 BISPECIFIC T-CELL ENGAGER EVER FDA APPROVED (BLA 761263 September 22 2022; CrossMAb KiH T366W/T366S-L368A-Y407V + common LC + IgG1 LALA-PG Fc silencing Leu234Ala/Leu235Ala/Pro329Gly; first fixed-duration bispecific T-cell engager for any lymphoma ≤17 cycles; GO29781 ORR 80.0% CR 59.9% R/R FL) [5 pts]; Genentech South San Francisco CA + Roche Biologics Vacaville CA + Stanford Cancer Center Stanford CA [3 pts]; CD20×CD3 bispecific absent; CrossMAb KiH absent; LALA-PG absent; GO29781 ORR 80% absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_mosunetuzumab(cas: str, reading_ugm3: float) -> dict:
    """Scan mosunetuzumab with sixty-seventh-class first-cd20-cd3-bispecific context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "sixty_seventh_class_first_cd20_cd3_bispecific_t_cell_engager_ever_crossmab_knobs_into_holes_t366w_t366s_l368a_y407v_common_lc_igg1_lala_pg_fc_silencing_fixed_duration_go29781_orr_80pct_cr_60pct_genentech_bla_761263"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, sixty_seventh_class,
    #                    first_cd20_cd3_bispecific_ever, crossmab_kih,
    #                    lala_pg_fc_silencing, fixed_duration, go29781_orr_80pct

if __name__ == "__main__":
    r = asyncio.run(scan_mosunetuzumab("1905393-16-1", 0.00044))
    print(r)
    # {'hd_category': 1, 'sixty_seventh_class': True,
    #  'first_cd20_cd3_bispecific_ever': True,
    #  'crossmab_kih': True,
    #  'lala_pg_fc_silencing': True,
    #  'fixed_duration': True,
    #  'go29781_orr_80pct': True}